Vimarsana
Biggest News Aggregation in the World

Page 5 - Philips Electronics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Philips Electronics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Philips Electronics Today - Breaking & Trending Today

Prime Medicine Announces FDA Clearance Of IND Application For Pm359 - Vimarsana News

Prime Medicine Announces FDA Clearance Of IND Application For Pm359

Prime Medicine, Inc. (PRME) announced the FDA has cleared the company's Investigational New Drug application for PM359 for the treatment of chronic granulomatous disease, enabling the company to initiate global Phase 1/2 clinical trial in the United States.

ON Semiconductor Guides Q2 Well Below Estimates - Vimarsana News

ON Semiconductor Guides Q2 Well Below Estimates

While reporting financial results for the first quarter on Monday, ON Semiconductor Corp. (ON) provided earnings and revenue guidance for the second quarter of fiscal 2024.

KORE Group CEO Romil Bahl To Resign, Ronald Totton To Be Interim CEO; Stock Down - Vimarsana News

KORE Group CEO Romil Bahl To Resign, Ronald Totton To Be Interim CEO; Stock Down

IoT solutions and services company, KORE Group Holdings, Inc. (KORE), Monday announced that President and Chief Executive Officer Romil Bahl will step down from the position, and will be replaced by Ronald Totton on an interim basis, effective May 3.

NKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Vimarsana News

NKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy

Https://www.globenewswire.com/news-release/2024/04/29/2871205/0/en/NKGen-Biotech-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-SNK01-NK-Cell-Therapy-in-Parkinson-s-Disease.

Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod - Vimarsana News

Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod

Abbott Laboratories (ABT) Monday announced that the U.S. Food and Drug Administration has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System for patients suffering from chronic limb-threatening ischemia below-the-knee or CLTI-BTK.